CCCC Q2 2020 Earnings — C4 Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CCCCC4 Therapeutics, Inc.

$239M

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M+147.7% YoY

Gross Profit

$10M100.0% margin

Operating Income

-$11M-112.3% margin

Net Income

-$11M-111.6% margin

EPS (Diluted)

$-0.26

QoQ Revenue Growth

+41.9%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$14M

Stock-Based Comp.

$161,000

Balance Sheet

Total Assets

$248M

Total Liabilities

$124M

Stockholders' Equity

$124M

Cash & Equivalents

$112M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$4M	+147.7%
Gross Profit	$10M	-$6M	+271.4%
Operating Income	-$11M	-$7M	-45.2%
Net Income	-$11M	-$9M	-18.7%